These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 17014391)

  • 41. Predictive, non-GLP models of secondary pharmacodynamics: putting the best compounds forward.
    Reinhart GA; Fryer RM; Osinski MA; Polakowski JS; Cox BF; Gintant GA
    Curr Opin Chem Biol; 2005 Aug; 9(4):392-9. PubMed ID: 15950522
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
    Zhu M; Zhang D; Zhang H; Shyu WC
    Biopharm Drug Dispos; 2009 May; 30(4):163-84. PubMed ID: 19544287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-throughput screening, metabolomics and drug discovery.
    Harrigan GG; Yates LA
    IDrugs; 2006 Mar; 9(3):188-92. PubMed ID: 16523384
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current in vitro and in silico models of blood-brain barrier penetration: a practical view.
    Vastag M; Keseru GM
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):115-24. PubMed ID: 19152220
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening.
    Rishton GM
    Curr Opin Chem Biol; 2008 Jun; 12(3):340-51. PubMed ID: 18328272
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Embryo-fetal toxicity signals for 17alpha-hydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins.
    Christian MS; Brent RL; Calda P
    J Matern Fetal Neonatal Med; 2007 Feb; 20(2):89-112. PubMed ID: 17437208
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.
    Hosea NA; Collard WT; Cole S; Maurer TS; Fang RX; Jones H; Kakar SM; Nakai Y; Smith BJ; Webster R; Beaumont K
    J Clin Pharmacol; 2009 May; 49(5):513-33. PubMed ID: 19299532
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Computational toxicology--a tool for early safety evaluation.
    Merlot C
    Drug Discov Today; 2010 Jan; 15(1-2):16-22. PubMed ID: 19835978
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modelling in vitro hepatotoxicity using molecular interaction fields and SIMCA.
    Clark RD; Wolohan PR; Hodgkin EE; Kelly JH; Sussman NL
    J Mol Graph Model; 2004 Jul; 22(6):487-97. PubMed ID: 15182808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimization of pharmaceutical formulations for therapy.
    Kofi-Tsekpo MW
    Afr J Health Sci; 1994 Feb; 1(1):13-19. PubMed ID: 12150638
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery.
    Li C; Liu B; Chang J; Groessl T; Zimmerman M; He YQ; Isbell J; Tuntland T
    Drug Discov Today; 2013 Jan; 18(1-2):71-8. PubMed ID: 22982770
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Strategy of molecular design of drugs: the unification of macro-properties and micro-structures of a molecule].
    Guo ZR
    Yao Xue Xue Bao; 2008 Mar; 43(3):227-33. PubMed ID: 18630256
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dissimilarity-based approaches to compound acquisition.
    Lajiness M; Watson I
    Curr Opin Chem Biol; 2008 Jun; 12(3):366-71. PubMed ID: 18423415
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Avoiding physicochemical artefacts in early ADME-Tox experiments.
    DeWitte RS
    Drug Discov Today; 2006 Sep; 11(17-18):855-9. PubMed ID: 16935755
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploration of the African green monkey as a preclinical pharmacokinetic model: oral pharmacokinetic parameters and drug-drug interactions.
    Ward KW; Coon DJ; Magiera D; Bhadresa S; Struharik M; Lawrence MS
    Xenobiotica; 2009 Mar; 39(3):266-72. PubMed ID: 19280525
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Formulations strategies for biopharmaceuticals--ensuring success to market.
    Atkinson EM; Klum W
    IDrugs; 2001 May; 4(5):557-60. PubMed ID: 16012901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Understanding mechanisms of toxicity: insights from drug discovery research.
    Houck KA; Kavlock RJ
    Toxicol Appl Pharmacol; 2008 Mar; 227(2):163-78. PubMed ID: 18063003
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems.
    Dixit R; Coats S
    IDrugs; 2009 Feb; 12(2):103-8. PubMed ID: 19204884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.